Improving patient and caregiver understanding of risks and benefits of immunotherapy for melanoma or lung cancer.

Authors

null

Laura A Petrillo

Massachusetts General Hospital and Harvard Medical School, Boston, MA

Laura A Petrillo , Ashley Zhou , Angelo E. Volandes , Ryan J. Sullivan , Areej El-Jawahri , Joseph A. Greer , Jennifer S. Temel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Quality Improvement

Clinical Trial Registration Number

04670445

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS6596)

DOI

10.1200/JCO.2021.39.15_suppl.TPS6596

Abstract #

TPS6596

Poster Bd #

Online Only

Abstract Disclosures

Funded by Conquer Cancer

Similar Posters

First Author: Vincenzo Quagliariello

Poster

2023 ASCO Annual Meeting

Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.

Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.

First Author: Yongzhao Li

First Author: Fang Yang

First Author: Ayo Samuel Falade